SCHEMBL3090856

SCHEMBL3090856

COC(=O)c1ccc2c(C3CCCCC3)c3n(c2c1)CCN(CC(=O)OC(C)(C)C)Cc1ccccc1-3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.39
MMP12 P39900 1/20 0.39
NR1I2 O75469 2/20 0.38
SCN9A Q15858 2/20 0.38
HTR4 Q13639 1/20 0.36
CNR2 P34972 1/20 0.35
USP14 P54578 1/20 0.35
PDGFRB P09619 1/20 0.35
FGFR1 P11362 1/20 0.35
PDGFRA P16234 1/20 0.35
FLT1 P17948 1/20 0.35
FGFR3 P22607 1/20 0.35
KDR P35968 1/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3097455 0.90 PRKCA (0.43) PRKCAMMP12NR1I2SCN9ACNR2
SCHEMBL12429621 0.86 NR1H2 (0.43) PRKCAMMP12NR1I2SCN9A
SCHEMBL14572855 0.86 PRKCA (0.40) PRKCAMMP12NR1I2SCN9ACNR2
SCHEMBL3090937 0.84 NR1I2 (0.47) PRKCAMMP12NR1I2SCN9ACNR2
SCHEMBL3087256 0.84 PRKCA (0.48) PRKCAMMP12NR1I2SCN9ACYP3A4
SCHEMBL12429623 0.83 SCN9A (0.43) PRKCAMMP12NR1I2SCN9ACYP3A4
SCHEMBL4823223 0.83 NR1I2 (0.47) PRKCAMMP12NR1I2SCN9ACYP3A4
SCHEMBL772587 0.81 SCN9A (0.47) PRKCAMMP12NR1I2SCN9AALDH1A1
SCHEMBL3087390 0.81 PRKCA (0.39) PRKCAMMP12NR1I2SCN9ACNR2
SCHEMBL771196 0.81 SCN9A (0.49) PRKCAMMP12NR1I2SCN9ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795247-B2 Tetracyclic indole derivatives as antiviral agents ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-09-14 US disclosed
EP-1807403-A2 TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2007-07-18 EP disclosed
US-20060100262-A1 Tetracyclic indole derivatives as antiviral agents ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) 2006-05-11 US disclosed
WO-2006046030-A2 TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100262-A1 Tetracyclic indole derivatives as antiviral agents IDO1, ZC3HAV1, IDO2 PRKCA 3874/4885MMP12 3319/4885NR1I2 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.